Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of Olanzapine for Elderly Patients with Psychotic Disorders: A Review

Use of Olanzapine for Elderly Patients with Psychotic Disorders: A Review The number of elderly persons with psychosis will increase with the increasing geriatric population. Olanzapine is one of the newer atypical antipsychotics with efficacy for positive and negative symptoms and safer side effect profile compared to conventional antipsychotics. The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly. Further studies are needed to fully assess the efficacy and safety of olanzapine in the elderly. Current research supports a role for olanzapine in treating elderly patients with schizophrenia, schizoaffective disorder and behavioral and psychological symptoms of dementia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Use of Olanzapine for Elderly Patients with Psychotic Disorders: A Review

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/use-of-olanzapine-for-elderly-patients-with-psychotic-disorders-a-oSNtdkD13y
Publisher
Springer Journals
Copyright
Copyright © 2001 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1014674018039
Publisher site
See Article on Publisher Site

Abstract

The number of elderly persons with psychosis will increase with the increasing geriatric population. Olanzapine is one of the newer atypical antipsychotics with efficacy for positive and negative symptoms and safer side effect profile compared to conventional antipsychotics. The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly. Further studies are needed to fully assess the efficacy and safety of olanzapine in the elderly. Current research supports a role for olanzapine in treating elderly patients with schizophrenia, schizoaffective disorder and behavioral and psychological symptoms of dementia.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 19, 2004

References

  • The treatment of psychosis in late life
    Zagas, EM; Grossberg, GT
  • The treatment of psychotic disorders in late life
    Thorpe, L
  • The late onset of psychosis: Possible risk factors
    Pearlson, G; Rabins, P
  • Neuroleptic treatment of agitation and psychosis in dementia
    Devanand, DP; Levy, SR
  • Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients
    Jeste, DV; Caligiuri, MP; Paulsen, JS; Heaton, RK; Lacro, JP; Harris, MJ; Bailey, A; Fell, RL; McAdams, LA
  • Prospective study of tardive dyskinesia in the elderly
    Saltz, BL; Kane, JM; Woerner, MG; Lieberman, LA; Alvir, JM; Blank, K; Kahaner, K; Foley, C
  • Clinical assessments of extrapyramidal signs in nursing home patients given antipsychotic medication
    Avorn, J; Monane, M; Everitt, DE; Beers, MH; Fields, D
  • Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia
    Madhusoodanan, S; Brenner, R; Cohen, CL
  • Radioreceptor binding profile of the atypical antipsychotic olanzapine
    Bymaster, FP; Calligaro, DO; Falcone, JF; Marsh, RD; Moore, NA; Tye, NC; Seeman, P; Wong, DT
  • Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
    Schotte, A; Janssen, PFM; Gommeren, W; Luyten, WH; VanGompel, P; Lesage, AS; Deloore, K; Leysen, JE
  • Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKI values
    Meltzer, HY; Matsubara, S; Lee, J-C
  • Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (C)¡S 14297: II. Both D2 and “silent” D3 autoreceptors control synthesis and release in mesolimbic, mesocortical, and nigrostriatal pathways
    Gobert, A; Rivet, J-M; Audinot, V; Cistarelli, L; Spedding, M; Vian, J; Peglion, JL; Millan, MJ
  • Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, ®1-adrenergic and muscarinic receptors in vivo in rats
    Bymaster, FP; Hemrick-Luecke, SK; Perry, KW; Fuller, RW
  • Olanzapine for psychotic conditions in the elderly
    Street, JS; Tollefson, GD; Tohen, M; Sanger, TM; Clark, WS; Gannon, KS; Wei, H
  • Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
    Tollefson, GD; Beasley, CM; Tran, PV; Street, JS; Krueger, JA; Tamura, RN; Graffeo, KA; Thieme, ME
  • The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
    Kay, SR; Fiszbein, A; Opler, LA
  • The Brief Psychiatric Rating Scale
    Overall, JE; Gorham, DR
  • A new depression scale designed to be sensitive to change
    Montgomery, SA; Asburg, M
  • Drug-induced extrapyramidal disorders
    Simpson, GM; Angus, JWS
  • A rating scale for drug-induced akathisia
    Barnes, TR
  • ECDEU Assessment Manual for Psychopharmacology
    Guy, W.
  • Olanzapine therapy in elderly patients with schizophrenia
    Sajatovic, M; Perez, D; Brescan, D; Ramirez, LF
  • Mini Mental State. Apractical method for grading the cognitive state of patients by the clinician
    Folstein, MF; Folstein, SE; Hugh, PR
  • Effi-cacy and tolerability of olanzapine in elderly patients with psychotic disorders: A prospective study
    Madhusoodanan, S; Brenner, R; Suresh, P; Concepcion, NM; Florita, CD; Menon, G; Kaur, A; Nunez, G; Reddy, H
  • Extrapyramidal Symptoms Rating
    Chouinard, G; Ross-Chouinard, A; Annable, L; Jones, BD
  • Calgary Depression Scale for Schizophrenia: Depression rating scale for schizophrenics
    Addington, D; Addington, J; Schissel, BA
  • Experience with the atypical antipsychotics-Risperidone and Olanzapine in the elderly
    Madhusoodanan, S; Suresh, P; Brenner, R; Pillai, R
  • A rating scale for mania: Reliability, validity and sensitivity
    Young, RC; Biggs, JT; Ziegler, VE; Meyer, DA
  • Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): The CGI-BP
    Spearing, MK; Post, PM; Leverich, GS; Brandt, D; Nolen, W
  • Development of a rating scale for primary depressive illness
    Hamilton, M
  • Course of the manic depressive cycle and changes caused by treatment
    Kukopulos, A; Reginaldi, D; Laddomada, P; Floris, G; Serra, G; Tondo, L
  • A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients
    Satterlee, WG; Reams, SG; Burns, PR; Hamilton, S; Tran, PV; Tollefson, GD
  • Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
    Reisberg, B; Borenstein, J; Salob, SP; Ferris, SH; Franssen, E; Georgotas, A
  • Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomised, placebocontrolled trial. The HGEU Study Group
    Street, J; Clark, WS; Gannon, KS; Cummings, JL; Bymaster, FP; Tamura, RN; Mitan, SJ; Kadam, DL; Sanger, TM; Feldman, PD; Tolefson, GD; Breier, A
  • The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia
    Cummings, JL; Mega, M; Gray, K; Rosenberg-Thompson, S; Carusi, DA; Gorbein, J
  • Olanzapine use in the elderly: A retrospective analysis
    Solomons, K; Geiger, O
  • Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
    Wolters, EC; Jansen, EN; Tuynman-Qua, HG; Bergmans, PL
  • Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
    Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E
  • Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
    Goetz, CG; Blasucci, LM; Leurgans, S; Pappert, EJ
  • The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies
    Ballard, C; McKeith, I; Burn, D; Harrison, R; O'Brien, J; Lowery, K; Campbell, M; Perry, R; Ince, P
  • Deterioration of Parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine
    Rudolf, J; Ghaemi, M; Schmulling, S
  • Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open label pilot study
    Friedman, JH; Goldstein, S; Jacques, C
  • Worsening of motor features of Parkinsonism with olanzapine
    Molho, ES; Factor, SA
  • Olanzapine in dementia with Lewy bodies: A clinical study
    Walker, Z; Grace, J; Overshot, R; Satarasinghe, S; Swan, A; Katona, CL; McKeith, IG
  • Olanzapine in the treatment of delirium
    Sipahimalani, A; Masand, PS
  • Complicated delirium in a cancer patient successfully treated with olanzapine
    Passik, SD; Cooper, M
  • Olanzapine for the treatment of tardive dyskinesia [letter]
    Almeida, OP
  • Marked reduction of tardive dyskinesia with olanzapine
    Littrell, KH; Johnson, CG; Littrell, S; Peabody, CD
  • Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject [letter]
    O'Brien, J; Barber, R
  • Reduction of tardive dystonia with olanzapine [letter]
    Jaffe, ME; Simpson, GM
  • Olanzapine-induced tardive dystonia [letter]
    Dunayevich, E; Strakowski, SM
  • Tardive dyskinesia associated with olanzapine monotherapy [letter]
    Ananth, J; Kenan, J
  • Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
    Tollefson, GD; Beasley, CM; Tamura, RN; Tran, PV; Potvin, JH
  • Neuroleptic malignant syndrome associated with olanzapine
    Johnson, V; Bruxner, G
  • Recurrence of neuroleptic malignant syndrome with olanzapine treatment
    Gheorghiu, S; Knobler, HY; Drumer, D
  • Possible induction of mania and hypomania by olanzapine or risperidone: A critical review of reported cases
    Aubry, J-M; Simon, AE; Bertschy, G
  • Mania induced by olanzapine
    Benazzi, F; Rossi, E
  • Body Mass Index increase of 58% associated with olanzapine [letter]
    Bryden, KE; Kopala, LC
  • Olanzapine increases weight and serum triglyceride levels
    Osser, DN; Najarian, DM; Dufresne, RL
  • Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
    Melkersson, KI; Hulting, A-L; Brismar, KE
  • Olanzapine-induced weight gain
    Gupta, S; Droney, T; Al-Samarrai, S; Keller, P; Frank, B
  • Obesity and mortality: A review of the epidemiologic data
    Solomon, CG; Manson, JE
  • Hyperglycaemia and olanzapine [letter]
    Ober, SK; Hudak, R; Rusterholtz, A
  • Novel antipsychotics and new onset diabetes
    Wirshing, DA; Spellberg, BJ; Erhart, SM; Wirshing, WC
  • Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone
    Dernovsek, MK; Tavcar, R
  • Two cases of olanzapine-induced reversible neutropenia
    Steinwachs, A; Grohmann, R; Pedrosa, F; Ruther, E; Schwerdtner, I
  • Prolongation of clozapine-induced granulocytopenia associated with olanzapine [letter]
    Flynn, SW; Altman, S; MacEwan, GW; Black, LL; Greenidge, LL; Honer, WG
  • Olanzapine-induced acute pancreatitis
    Doucette, DE; Grenier, JP; Robertson, PS
  • Recurrent priapism during treatment with clozapine and olanzapine [letter]
    Compton, MT; Saldivia, A; Berry, SA
  • Priapism following olanzapine administration in a patient with multiple sclerosis
    Heckers, S; Anick, D; Boverman, JF; Stern, TA
  • Olanzapine-induced reversible priapism: A case report
    Deirmenjian, JM; Erhart, SM; Wirshing, DA; Spellberg, BJ; Wirshing, WC